SG11201509882WA - Methods and compositions for templated assembly of nucleic acid specific heterocompounds - Google Patents

Methods and compositions for templated assembly of nucleic acid specific heterocompounds

Info

Publication number
SG11201509882WA
SG11201509882WA SG11201509882WA SG11201509882WA SG11201509882WA SG 11201509882W A SG11201509882W A SG 11201509882WA SG 11201509882W A SG11201509882W A SG 11201509882WA SG 11201509882W A SG11201509882W A SG 11201509882WA SG 11201509882W A SG11201509882W A SG 11201509882WA
Authority
SG
Singapore
Prior art keywords
heterocompounds
compositions
methods
nucleic acid
acid specific
Prior art date
Application number
SG11201509882WA
Inventor
Ian Dunn
Matthew Lawler
Original Assignee
Tribiotica Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tribiotica Llc filed Critical Tribiotica Llc
Publication of SG11201509882WA publication Critical patent/SG11201509882WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1068—Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
SG11201509882WA 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds SG11201509882WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361831133P 2013-06-04 2013-06-04
PCT/US2014/040822 WO2014197547A1 (en) 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds

Publications (1)

Publication Number Publication Date
SG11201509882WA true SG11201509882WA (en) 2016-01-28

Family

ID=52008550

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201509882WA SG11201509882WA (en) 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds
SG10201710033PA SG10201710033PA (en) 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201710033PA SG10201710033PA (en) 2013-06-04 2014-06-04 Methods and compositions for templated assembly of nucleic acid specific heterocompounds

Country Status (12)

Country Link
US (2) US10603385B2 (en)
EP (1) EP3004351B1 (en)
JP (1) JP6710157B2 (en)
CN (1) CN105358691A (en)
AU (2) AU2014275010B2 (en)
CA (1) CA2950117C (en)
HK (1) HK1222201A1 (en)
IL (1) IL242797B (en)
MX (1) MX2015016371A (en)
SG (2) SG11201509882WA (en)
WO (1) WO2014197547A1 (en)
ZA (1) ZA201600024B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6710157B2 (en) 2013-06-04 2020-06-17 トリビオティカ・エルエルシー Methods and compositions for templated assembly of nucleic acid specific hetero compounds
US10704084B2 (en) 2014-12-02 2020-07-07 Tribiotica Llc Methods and kits for theranostic applications
EP3541952A4 (en) * 2016-11-21 2020-06-24 Tribiotica Llc Methods for preventing titration of bimolecular templated assembly reactions by structurally-determined differential hybridizations
US11253536B2 (en) 2016-11-21 2022-02-22 Tribiotica Llc Methods for directed folding assembly or dimerization of proteins by templated assembly reactions
CN110191953A (en) * 2016-11-21 2019-08-30 特里比奥迪卡有限责任公司 The method for realizing division protein template assembling by the reactivity close to enhancing
CN110982876B (en) * 2020-03-04 2020-05-26 圣湘生物科技股份有限公司 Pretreatment method, pretreatment liquid, kit and application of virus nucleic acid detection
WO2022099055A1 (en) * 2020-11-09 2022-05-12 The General Hospital Corporation Template assembly by proximity-enhanced reactivity via metabolic labeling

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020096A1 (en) 1991-05-08 1993-10-14 Stratagene Oligonucleotide libraries useful for producing primers
US5514546A (en) 1993-09-01 1996-05-07 Research Corporation Technologies, Inc. Stem-loop oligonucleotides containing parallel and antiparallel binding domains
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US20020172965A1 (en) 1996-12-13 2002-11-21 Arcaris, Inc. Methods for measuring relative amounts of nucleic acids in a complex mixture and retrieval of specific sequences therefrom
EP1208219A1 (en) 1999-04-08 2002-05-29 Pavel Sergeev Synthesis of biologically active compounds in cells
US7256259B2 (en) 2000-05-12 2007-08-14 Wisconsin Alumni Research Foundation Methods for ligation of molecules to surfaces
US7297494B2 (en) * 2001-06-25 2007-11-20 Georgia Tech Research Corporation Activatable probes and methods for in vivo gene detection
AU2003273472A1 (en) 2002-07-26 2004-02-16 Pierre Fabre Medicament Method for solubilizing hydrophobic peptides and use thereof for inducing an antitumoral and/or anti-infectious ctl response
PT1558744E (en) * 2002-10-30 2011-09-22 Nuevolution As Enzymatic encoding
US8420086B2 (en) * 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US20050026178A1 (en) 2003-03-28 2005-02-03 Marit Nilsen-Hamilton Allosteric probes and methods
DK1828381T3 (en) 2004-11-22 2009-02-23 Peter Birk Rasmussen Template-directed split-and-mix synthesis of small molecule libraries
CN100381460C (en) 2004-11-30 2008-04-16 北京市肿瘤防治研究所 HER-2 analogue antigen epitope and peptide containing said epitope
US20060147963A1 (en) * 2004-12-30 2006-07-06 Affymetrix, Inc. Detection of polynucleotides on nucleic acid arrays using azido-modified triphosphate nucleotide analogs
US7795009B2 (en) * 2005-06-15 2010-09-14 Saint Louis University Three-component biosensors for detecting macromolecules and other analytes
EP3591069A3 (en) * 2005-10-27 2020-03-04 The President and Fellows of Harvard College Methods and compositions for labeling nucleic acids
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
US8114636B2 (en) 2006-02-10 2012-02-14 Life Technologies Corporation Labeling and detection of nucleic acids
CA2649630C (en) 2006-04-20 2016-04-05 Silence Therapeutics Ag Lipoplex formulations for specific delivery to vascular endothelium
JP2009535323A (en) 2006-04-28 2009-10-01 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク Method for synthesizing oligonucleotide derivatives
US7674924B2 (en) 2006-05-22 2010-03-09 Third Wave Technologies, Inc. Compositions, probes, and conjugates and uses thereof
WO2008019123A2 (en) * 2006-08-04 2008-02-14 Georgia State University Research Foundation, Inc. Enzyme sensors, methods for preparing and using such sensors, and methods of detecting protease activity
US8410247B2 (en) 2008-08-22 2013-04-02 Wisconsin Alumni Research Foundation Water-soluble phosphinothiol reagents
FI20095302A0 (en) * 2009-03-24 2009-03-24 Arctic Partners Oy Ab Luminesenssimääritysmenetelmä
EP2454559B1 (en) * 2009-07-13 2013-05-01 Siemens Aktiengesellschaft Method for checking plausibility of digital measurement signals
GB201001088D0 (en) 2010-01-23 2010-03-10 Trillion Genomics Ltd Detection
WO2012057689A1 (en) 2010-10-29 2012-05-03 Ge Healthcare Bio-Sciences Ab Proximity ligation technology for western blot applications
CN111233978A (en) 2013-03-15 2020-06-05 普罗格诺西斯生物科学公司 Methods for detecting peptide/MHC/TCR binding
JP6710157B2 (en) 2013-06-04 2020-06-17 トリビオティカ・エルエルシー Methods and compositions for templated assembly of nucleic acid specific hetero compounds
WO2015122835A1 (en) 2014-02-13 2015-08-20 Ge Healthcare Bio-Sciences Ab Method for protein analysis
US10704084B2 (en) 2014-12-02 2020-07-07 Tribiotica Llc Methods and kits for theranostic applications
EP3350201B1 (en) 2015-09-18 2022-02-16 Agrivida, Inc. Engineered phytases and methods of using the same

Also Published As

Publication number Publication date
EP3004351B1 (en) 2018-08-08
IL242797B (en) 2021-12-01
AU2014275010B2 (en) 2020-10-29
MX2015016371A (en) 2017-02-15
US20210023227A1 (en) 2021-01-28
JP2016521714A (en) 2016-07-25
US20160106854A1 (en) 2016-04-21
CN105358691A (en) 2016-02-24
CA2950117C (en) 2023-02-14
US10603385B2 (en) 2020-03-31
ZA201600024B (en) 2019-04-24
AU2020256386A1 (en) 2020-11-12
AU2014275010A1 (en) 2015-12-17
EP3004351A4 (en) 2016-12-21
SG10201710033PA (en) 2018-01-30
JP6710157B2 (en) 2020-06-17
WO2014197547A1 (en) 2014-12-11
AU2020256386B2 (en) 2023-07-27
EP3004351A1 (en) 2016-04-13
NZ714546A (en) 2021-10-29
CA2950117A1 (en) 2014-12-11
HK1222201A1 (en) 2017-06-23

Similar Documents

Publication Publication Date Title
HK1213023A1 (en) Compositions and methods of nucleic acid-targeting nucleic acids
HK1219503A1 (en) Methods and compositions for nucleic acid sequencing
HK1222793A1 (en) Methods and compositions for inhibition of bromodomain-containing proteins
HUE045954T2 (en) Methods and compositions for preparing nucleic acid libraries
EP2958574A4 (en) Compositions and methods for genetic analysis of embryos
EP2971032A4 (en) Compositions and methods for nucleic acid extraction
AP3965A (en) Anthelminitic compounds and compositions and method of using thereof
EP3008181A4 (en) Methods and compositions for target dna modification
HK1221227A1 (en) Methods and compositions for nanostructure-based nucleic acid sequencing
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
HK1222201A1 (en) Methods and compositions for templated assembly of nucleic acid specific heterocompounds
EP2968244A4 (en) Compositions and methods for utilization of algal compounds
HK1223403A1 (en) Method for determining nucleic acid composition of nucleic acid mixture
HK1217518A1 (en) Compositions and methods of nucleic acid preparation and analyses
SG11201505891VA (en) Catalyst compositions and methods of making and using same
IL244033B (en) Methods and compositions for extraction and storage of nucleic acids
HK1223275A1 (en) Methods and compositions for prevention of allergic reaction
ZA201600927B (en) Structural assembly and method of assembly thereof
EP2906041A4 (en) Compositions and methods of use of an inappetance-controlling compound
SG11201600754PA (en) Compositions and methods for multimodal analysis of cmet nucleic acids
EP2968246A4 (en) Omega-3 pentaenoic acid compositions and methods of use
SG11201600755TA (en) Compositions and methods for multiplex analysis of nras and braf nucleic acids
IL240734A0 (en) Methods and compositions for preparation of nucleic acids
HK1207589A1 (en) Polymorphic forms of icotinib phosphate and uses thereof
TWM475581U (en) Analysis system of behavior